Information

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Retrieved on: 
Wednesday, April 10, 2024
Mallinckrodt, Financial management, University, Information, Treasury, Sharecare, United Therapeutics, Virginia School for Girls, Hereditary angioedema, Acquisition, Accounting, HAE, Therapy, Amphastar Pharmaceuticals, Strategic planning, Management

In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations.

Key Points: 
  • In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations.
  • “David expands Pharvaris’ leadership capabilities as we become a late-stage biotech company with an exciting pipeline and strong commercial potential,” said Berndt Modig, Chief Executive Officer of Pharvaris.
  • He will work closely on investor relations and corporate strategy with Morgan Conn, our Chief Business Officer.
  • Over his career, Mr. Nassif has served as the Chief Financial Officer of Histogen, Zogenix, Amphastar Pharmaceuticals, and RealAge.

Insteel Industries Reports Second Quarter 2024 Results

Retrieved on: 
Thursday, April 25, 2024
Building Systems, Manufacturing, Other Construction & Property, Steel, Construction & Property, Information, Capital expenditure, Plant, Weakness, Environment, Pressure, Growth, Video game

Insteel Industries Inc. (NYSE: IIIN) (“Insteel” or the “Company”), the largest manufacturer of steel wire reinforcing products for concrete construction applications in the United States, today announced financial results for its second quarter of fiscal 2024 ended March 30, 2024.

Key Points: 
  • Insteel Industries Inc. (NYSE: IIIN) (“Insteel” or the “Company”), the largest manufacturer of steel wire reinforcing products for concrete construction applications in the United States, today announced financial results for its second quarter of fiscal 2024 ended March 30, 2024.
  • Insteel’s results for the second quarter benefited from widening spreads between selling prices and raw material costs relative to the prior year quarter.
  • Insteel ended the quarter debt-free with $83.9 million of cash and no borrowings outstanding on its $100.0 million revolving credit facility.
  • ET today to discuss its second quarter financial results.

Scrum Alliance® Appoints Veteran Transformation Leader Chetna Limbani as Its First Chief Delivery Officer

Retrieved on: 
Thursday, April 25, 2024
Technology, Consulting, Professional Services, Other Technology, SMU, Information, Texas A&M University–Commerce, Economics, PSM, History, Professional, Agile, ASCAP, Multimedia, Management

Scrum Alliance , the largest, most established and influential professional membership and certification organization in the agile community, is proud to announce its first chief delivery officer.

Key Points: 
  • Scrum Alliance , the largest, most established and influential professional membership and certification organization in the agile community, is proud to announce its first chief delivery officer.
  • Chetna Limbani, with 25 years of industry and management consulting experience, will serve in this role.
  • View the full release here: https://www.businesswire.com/news/home/20240425533607/en/
    As SAI’s chief delivery officer, Limbani will lead the successful execution of the nonprofit’s enterprise-wide transformation initiatives.
  • I am confident that she will greatly assist in growing the company's capabilities even further and provide outstanding leadership as the Chief Delivery Officer of Scrum Alliance."

Graco Reports First Quarter Results

Retrieved on: 
Wednesday, April 24, 2024
Manufacturing, Other Manufacturing, Other Construction & Property, Construction & Property, Chemicals, Plastics, Graco, Information, Risk, Annual report, Security (finance), Webcast, Intelligence, Intellectual property, Cryptocurrency

Forward-looking statements are based upon currently available information, but various risks and uncertainties may cause our Company’s actual results to differ materially from those expressed in these statements.

Key Points: 
  • Forward-looking statements are based upon currently available information, but various risks and uncertainties may cause our Company’s actual results to differ materially from those expressed in these statements.
  • Future results could differ materially from those expressed, due to the impact of changes in various factors.
  • These reports are available on the Company’s website at www.graco.com and the Securities and Exchange Commission’s website at www.sec.gov .
  • ET, 10 a.m. CT, to discuss Graco’s first quarter results.

DISA Validates Security Technical Implementation Guide (STIG) for Mirantis Kubernetes Engine

Retrieved on: 
Wednesday, April 24, 2024
Defense, Security, Apps, Applications, Technology, Software, Military, Networks, Container, Public sector, Organization, Information, MKE, Department of Defence, DISA, Environment, FedRAMP, Security Technical Implementation Guide, Government, Medical device

Mirantis , providing organizations with total control over their strategic infrastructure using open source software, today announced the Defense Information Systems Agency (DISA) has published and validated the Security Technical Implementation Guide (STIG) for Mirantis Kubernetes Engine (MKE) – also sold as Containers as a Service-Government (CAAS-G) in public sector markets.

Key Points: 
  • Mirantis , providing organizations with total control over their strategic infrastructure using open source software, today announced the Defense Information Systems Agency (DISA) has published and validated the Security Technical Implementation Guide (STIG) for Mirantis Kubernetes Engine (MKE) – also sold as Containers as a Service-Government (CAAS-G) in public sector markets.
  • Future releases of MKE can be quickly validated, and the corresponding STIG updates published by Mirantis – working in cooperation with DISA, who maintains the model STIGs for upstream Kubernetes and the DevSecOps reference design for CNCF Kubernetes .
  • STIG validation is a security review and configuration standard that helps ensure IT products and military agencies are complying with DoD security policies.
  • The STIG for MKE includes technical guidance for establishing a secure software supply chain using the platform.

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Information, Acalabrutinib, Colorectal cancer, BCL2, Follicular lymphoma, Patient, Comparison, TIS, HPK1, Tislelizumab, Lymphoid leukemia, Pharmaceutical industry

Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based analysis

Key Points: 
  • Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based analysis
    Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL)
    BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia
    Session Type and Title: Poster Session – Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
    Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: an open-label, single-arm, multicenter phase II study
    Tislelizumab First-Line (1L) Gastric/Gastroesophageal Junction Cancer (G/GEJ) Treatment Efficacy on PRO-Based Symptom Endpoints Adjusting for Informative Missing Data Bias: Results from RATIONALE 305
    A first‑in‑human phase 1a dose‑escalation study of BGB‑15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti‑PD‑1 antibody) in patients (pts) with advanced solid tumors
    Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.

IANS Research Receives Strategic Investment From the Apax Digital Funds to Accelerate Growth and Market Leadership in Information Security

Retrieved on: 
Tuesday, April 23, 2024
Technology, Consulting, Security, Professional Services, Software, Networks, Internet, Data Analytics, Data Management, Risk, Information, CISO, Research, Centerview Partners, Financial adviser, Digital, Faculty, Information services, Organization, Growth, Medical device

IANS Research, the leading provider of independent research and advisory services for the information security industry, has announced a new strategic investment from the Apax Digital Fund II (the “Apax Digital Funds”).

Key Points: 
  • IANS Research, the leading provider of independent research and advisory services for the information security industry, has announced a new strategic investment from the Apax Digital Fund II (the “Apax Digital Funds”).
  • The investment from the Apax Digital Funds will enable IANS to accelerate product development, expand its value proposition, and scale its go-to-market efforts.
  • The Apax Digital team’s deep expertise in information security and tech-enabled information services positions the Funds well to partner with IANS and its management team to drive growth and fuel the next stage of the company’s evolution.
  • The investment and deep industry expertise of the Apax Digital team will equip us with the tools to accelerate our growth.

Verafin Enhances Financial Crime Management Solutions Suite with Launch of Entity Research Copilot — First of Its Integrated Copilot Capabilities

Retrieved on: 
Monday, April 22, 2024
Data Management, Technology, Professional Services, Security, Other Technology, Apps, Applications, Software, Artificial Intelligence, Other Professional Services, Fintech, Finance, Product strategy, Fraud, NDAQ, News, EVP, AI, Machine learning, Information, Research, AML, Artificial intelligence, Workflow, History, Automation, First officer (aviation), Crime, Terrorism, Face, Brother, Cryptocurrency

Verafin, a Nasdaq company, renowned for its expertise in applying artificial intelligence (AI) and big data technologies to fight crime, announces the launch of Entity Research Copilot, the first of its integrated Copilot capabilities, bolstering its suite of financial crime management solutions.

Key Points: 
  • Verafin, a Nasdaq company, renowned for its expertise in applying artificial intelligence (AI) and big data technologies to fight crime, announces the launch of Entity Research Copilot, the first of its integrated Copilot capabilities, bolstering its suite of financial crime management solutions.
  • Following an extensive Beta program, Verafin is rolling out availability of its first copilot feature, the integrated Entity Research Copilot, to its customer base of more than 2,500 financial institutions.
  • Leveraging multiple automation technologies, including generative AI (GenAI), Verafin’s Financial Crime Management Copilot capabilities automates compliance tasks and daily workflows to reduce operational costs and increase the efficiency of anti-financial crime programs.
  • “Our Copilot capabilities represent the latest evolution of our industry-leading financial crime management solutions,” said Brendan Brothers, EVP, Financial Crime Management Technology, Nasdaq and Co-founder, Verafin.

Employers Mutual Limited Insures Risk Management with SentinelOne®

Retrieved on: 
Monday, April 22, 2024
Software, Insurance, Internet, Artificial Intelligence, Data Management, Professional Services, Technology, Security, SentinelOne, EML, Risk, AI, Environment, Government, Information, Organization, Employers Mutual Limited, Linux

As an insurer, Employers Mutual Limited (EML) knows a few things about risk.

Key Points: 
  • As an insurer, Employers Mutual Limited (EML) knows a few things about risk.
  • And the injury management specialist has selected SentinelOne (NYSE: S), a global leader in AI-powered security, as its platform to mitigate it.
  • “Security is a huge driver for our business,” said Hayden MacKellar, Information and Security Risk Manager, EML.
  • “We manage workers compensation insurance and claims for employers and government agencies across Australia, and we have to ensure that the systems we run protect the sensitive data we deal with.

Cytonus Therapeutics Expands C-suite as it Transitions to a Clinical Stage Company

Retrieved on: 
Monday, April 22, 2024
Health, Infectious Diseases, Health Technology, General Health, Pharmaceutical, Biotechnology, Doctor of Philosophy, Administration, University, LEGO, Information, Master of Business Administration, M.B.A, Intellectual property, Commercialization, Partnering, McKinsey & Company, Business administration, Corporate development, Duke University, Senior, Patent, Bachelor of Arts, Virginia Tech, Medical school, Physician, Therapy, Management

Cytonus Therapeutics, Inc., a biotherapeutic company developing transformative medicines based on next generation drug-delivery platform technology called Cargocytes™, announced today that Mickey Kim, M.D., M.B.A. has joined the company as Chief Business Officer.

Key Points: 
  • Cytonus Therapeutics, Inc., a biotherapeutic company developing transformative medicines based on next generation drug-delivery platform technology called Cargocytes™, announced today that Mickey Kim, M.D., M.B.A. has joined the company as Chief Business Officer.
  • In addition, Cytonus has added Sherry M. Carty, Ph.D., as Director of Intellectual Property and Karen Markham has been promoted to Chief Administrative Officer.
  • Prior to Inova, he was a member of MedImmune/AstraZeneca's Partnering & Strategy Leadership Team, a healthcare venture capitalist and a strategy consultant with McKinsey and Company.
  • Mrs. Markham has been promoted to Chief Administrative Officer at Cytonus, where she oversees all administrative functions.